Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Value of Different Magnetic Resonance Imaging-based Measurements of Anatomical Structures on Preoperative Prostate Imaging in Predicting Urinary Continence After Radical Prostatectomy in Men with Prostate Cancer: A Systematic Review and Meta-analysis.
van Dijk-de Haan MC, Boellaard TN, Tissier R, Heijmink SWTPJ, van Leeuwen PJ, van der Poel HG, Schoots IG. van Dijk-de Haan MC, et al. Among authors: van leeuwen pj, van der poel hg. Eur Urol Focus. 2022 Sep;8(5):1211-1225. doi: 10.1016/j.euf.2022.01.015. Epub 2022 Feb 15. Eur Urol Focus. 2022. PMID: 35181284
Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100).
Roobol MJ, Schröder FH, van Leenders GL, Hessels D, van den Bergh RC, Wolters T, van Leeuwen PJ. Roobol MJ, et al. Among authors: van leenders gl, van den bergh rc, van leeuwen pj. Eur Urol. 2010 Dec;58(6):893-9. doi: 10.1016/j.eururo.2010.09.030. Epub 2010 Sep 26. Eur Urol. 2010. PMID: 20933321 Clinical Trial.
A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial.
Wolters T, Roobol MJ, van Leeuwen PJ, van den Bergh RC, Hoedemaeker RF, van Leenders GJ, Schröder FH, van der Kwast TH. Wolters T, et al. Among authors: van den bergh rc, van leenders gj, van leeuwen pj, van der kwast th. J Urol. 2011 Jan;185(1):121-5. doi: 10.1016/j.juro.2010.08.082. Epub 2010 Nov 12. J Urol. 2011. PMID: 21074212
Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X, van Leeuwen PJ, Bul M, Otto SJ, de Koning HJ, Bangma CH, Schröder FH, Roobol MJ. Zhu X, et al. Among authors: van leeuwen pj. Eur Urol. 2011 Aug;60(2):330-6. doi: 10.1016/j.eururo.2011.05.013. Epub 2011 May 17. Eur Urol. 2011. PMID: 21601352 Clinical Trial.
Towards an optimal interval for prostate cancer screening.
van Leeuwen PJ, Roobol MJ, Kranse R, Zappa M, Carlsson S, Bul M, Zhu X, Bangma CH, Schröder FH, Hugosson J. van Leeuwen PJ, et al. Eur Urol. 2012 Jan;61(1):171-6. doi: 10.1016/j.eururo.2011.08.002. Epub 2011 Aug 10. Eur Urol. 2012. PMID: 21840117 Clinical Trial.
232 results